Clinical Trial: A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

U.S., July 1 -- ClinicalTrials.gov registry received information related to the study (NCT07676266) titled 'A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy' on June 24.

Brief Summary: This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy

Study Start Date: July, 2026

Study Type: INTERVENTIONAL

Condition: Multiple Sclerosis (MS) Myasthenia Gravis (MG) Neuromyelitis Optica Spectrum Disorder Systemic Lupus Erythematosus Systemic Sclerosis Immune-Mediated Necrotizing Myopathy

Intervention: BIOLOGICAL: CD20/BCMA-direc...